Literature DB >> 11449374

Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.

B L Perlaza1, J P Sauzet, A T Balde, K Brahimi, A Tall, G Corradin, P Druilhe.   

Abstract

We synthesized 17 long synthetic peptides (LSP) spanning the whole 200-kDa Plasmodium falciparum liver stage antigen-3 (LSA3), an antigen that induces protection in chimpanzee, and analyzed their immunogenicity in BALB/c mice and their antigenicity in individuals living in a hyper-endemic malaria area. Our findings show that both specific antibodies and T cell proliferation against most LSA3-LSP develop in malaria-exposed adults. All individuals studied had detectable antibodies against a minimum of 6 and a maximum of 15 polypeptides. It is noteworthy that antibody prevalence and titers were as high against non-repeat as repeat regions. Although the extent of T cell reactivity was lower than that observed for B cells, most of the sequences contained at least one T helper epitope, indicating that the majority of LSA3-LSP contain both B and T cell epitopes within the same sequence. Injection of LSA3-LSP with SBSA2 adjuvant in mice, showed strong immunogenicity for most of them, eliciting both T cell responses and specific antibody production. While all the peptides were immunogenic for B cells, different patterns of T cell responses were induced. These peptides were thus classified in three sets according to the levels of the T cell proliferative and of the IFN-gamma-specific responses. Importantly, antibodies and T cells against some of the LSP were able to recognize LSA3 native protein on P. falciparum sporozoites. Additionally, some LSP (44-119, 1026-1095, 1601-1712) also contained epitopes recognized by H-2(d) class I-restricted T cells. These results led to the identification of numerous domains that are highly antigenic and immunogenic within the LSA3 protein, and underline the value of the LSP approach for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11449374     DOI: 10.1002/1521-4141(200107)31:7<2200::aid-immu2200>3.0.co;2-l

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of Plasmodium falciparum infection.

Authors:  Hyeong-Woo Lee; Sung-Ung Moon; Hye-Sun Ryu; Yeon-Joo Kim; Shin-Hyeong Cho; Gyung-Tae Chung; Khin Lin; Byoung-Kuk Na; Yoon Kong; Kyung-Suk Chung; Tong-Soo Kim
Journal:  Korean J Parasitol       Date:  2006-03       Impact factor: 1.341

Review 2.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

3.  Multiple antigen peptide vaccines against Plasmodium falciparum malaria.

Authors:  Babita Mahajan; Jay A Berzofsky; Robert A Boykins; Victoria Majam; Hong Zheng; Rana Chattopadhyay; Patricia de la Vega; J Kathleen Moch; J David Haynes; Igor M Belyakov; Hira L Nakhasi; Sanjai Kumar
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

4.  Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages.

Authors:  Eva M Moyano; Luis Miguel González; Susana Arahuetes; Agustín Benito
Journal:  Parasitol Res       Date:  2007-09-09       Impact factor: 2.289

5.  Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.

Authors:  Lbachir BenMohamed; Alan Thomas; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

6.  Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.

Authors:  Aissatou Toure-Balde; Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Mouhamadou Ndiaye; Georgette Aribot; Adama Tall; Cheikh Sokhna; Christophe Rogier; Giampietro Corradin; Christian Roussilhon; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

7.  Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar.

Authors:  Tong-Soo Kim; Hyung-Hwan Kim; Jung-Yeon Kim; Yoon Kong; Byoung-Kuk Na; Khin Lin; Sung-Ung Moon; Yeon-Joo Kim; Myoung-Hee Kwon; Youngjoo Sohn; Hyuck Kim; Hyeong-Woo Lee
Journal:  Malar J       Date:  2011-08-06       Impact factor: 2.979

8.  Assessment of exposure to Plasmodium falciparum transmission in a low endemicity area by using multiplex fluorescent microsphere-based serological assays.

Authors:  Jean Biram Sarr; Eve Orlandi-Pradines; Sonia Fortin; Cheikh Sow; Sylvie Cornelie; François Rogerie; Soihibou Guindo; Lassana Konate; Thierry Fusaï; Gilles Riveau; Christophe Rogier; Franck Remoue
Journal:  Parasit Vectors       Date:  2011-11-07       Impact factor: 3.876

9.  Optimized expression of Plasmodium falciparum erythrocyte membrane protein 1 domains in Escherichia coli.

Authors:  Kirsten Flick; Sanjay Ahuja; Arnaud Chene; Maria Teresa Bejarano; Qijun Chen
Journal:  Malar J       Date:  2004-12-15       Impact factor: 2.979

10.  The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas.

Authors:  Eric Prieur; Pierre Druilhe
Journal:  Malar J       Date:  2009-10-29       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.